MX2010000937A - Tratamiento del trastorno por estrés postraumático. - Google Patents

Tratamiento del trastorno por estrés postraumático.

Info

Publication number
MX2010000937A
MX2010000937A MX2010000937A MX2010000937A MX2010000937A MX 2010000937 A MX2010000937 A MX 2010000937A MX 2010000937 A MX2010000937 A MX 2010000937A MX 2010000937 A MX2010000937 A MX 2010000937A MX 2010000937 A MX2010000937 A MX 2010000937A
Authority
MX
Mexico
Prior art keywords
post
stress disorder
traumatic stress
patient
compound
Prior art date
Application number
MX2010000937A
Other languages
English (en)
Spanish (es)
Inventor
Tom Woiwode
Mark Moran
Original Assignee
Synosia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synosia Therapeutics Inc filed Critical Synosia Therapeutics Inc
Publication of MX2010000937A publication Critical patent/MX2010000937A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MX2010000937A 2007-07-23 2008-07-23 Tratamiento del trastorno por estrés postraumático. MX2010000937A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93503607P 2007-07-23 2007-07-23
PCT/US2008/070948 WO2009015248A1 (en) 2007-07-23 2008-07-23 Treatment of post-traumatic stress disorder

Publications (1)

Publication Number Publication Date
MX2010000937A true MX2010000937A (es) 2010-06-25

Family

ID=40281815

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010000937A MX2010000937A (es) 2007-07-23 2008-07-23 Tratamiento del trastorno por estrés postraumático.

Country Status (12)

Country Link
US (1) US20090054403A1 (cg-RX-API-DMAC7.html)
EP (1) EP2182952A4 (cg-RX-API-DMAC7.html)
JP (1) JP2010534676A (cg-RX-API-DMAC7.html)
CN (1) CN101951912A (cg-RX-API-DMAC7.html)
AU (1) AU2008279091A1 (cg-RX-API-DMAC7.html)
CA (1) CA2707858A1 (cg-RX-API-DMAC7.html)
CO (1) CO6260078A2 (cg-RX-API-DMAC7.html)
MX (1) MX2010000937A (cg-RX-API-DMAC7.html)
NZ (1) NZ583193A (cg-RX-API-DMAC7.html)
RU (1) RU2458691C2 (cg-RX-API-DMAC7.html)
SG (1) SG183069A1 (cg-RX-API-DMAC7.html)
WO (1) WO2009015248A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010000938A (es) * 2007-07-23 2010-07-01 Synosia Therapeutics Inc Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del ácido 4-hidroxi-4-metil-piperidin-1-carboxílico para el tratamiento del trastorno por estrés postraumático.
RU2491067C2 (ru) * 2007-08-06 2013-08-27 Байотай Терапис, Инк Способы лечения зависимости
AU2016208412A1 (en) * 2007-08-06 2016-08-18 Biotie Therapies, Inc. Methods for treating dependence
PT2501234T (pt) * 2009-11-20 2017-12-13 Tonix Pharma Holdings Ltd Métodos e composições para o tratamento de sintomas associados com distúrbios de stress pós-traumático utilizando ciclobenzaprina
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
MY196014A (en) 2013-03-15 2023-03-06 Tonix Pharmaceuticals Inc Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride
EP3074525B1 (en) * 2013-11-26 2024-06-26 University of North Texas Health Science Center at Fort Worth Personalized medicine approach for treating cognitive loss
SG10201902203VA (en) 2014-09-18 2019-04-29 Tonix Pharma Holdings Ltd Eutectic formulations of cyclobenzaprine hydrochloride
RU2614697C1 (ru) * 2016-04-12 2017-03-28 Общество с ограниченной ответственностью "Нормофарм" Нейропротекторное средство
JOP20190049A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز
US10588890B2 (en) * 2017-05-30 2020-03-17 Biommunity, Inc. Compositions and methods to regulate hormonal cascades in stress disorders
AU2018204843B2 (en) * 2017-07-05 2023-07-27 Medtronic Ardian Luxembourg S.A.R.L. Methods for treating anxiety disorders in patients via renal neuromodulation
WO2019112457A1 (en) 2017-12-04 2019-06-13 BIAL - PORTELA & Cª, S.A. Dopamine-β-hydroxylase inhibitors
BR112020011345A2 (pt) 2017-12-11 2020-11-17 Tonix Pharma Holdings Limited tratamento com ciclobenzaprina para agitação, psicose e declínio cognitivo na demência e condições neurodegenerativas
CN109966281B (zh) * 2019-04-11 2021-04-27 北京大学 PAO作为Pi4KIIα抑制剂在制备治疗创伤后应激障碍药物中的应用
JP7618230B2 (ja) * 2019-07-25 2025-01-21 学校法人東京理科大学 精神・神経系の疾患又は症状を治療し、予防し又は改善する剤
CN120882371A (zh) * 2022-11-30 2025-10-31 闪烁实验室有限公司 使用眼睑跟踪的精神药理学系统和方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
EP1425017A1 (en) * 2001-09-13 2004-06-09 Schering Corporation Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
EP1336406A1 (en) * 2002-02-14 2003-08-20 Solvay Pharmaceuticals B.V. Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity
MXPA04011529A (es) * 2002-04-24 2005-08-15 Cypress Bioscience Inc Prevencion y tratamiento de trastornos somaticos funcionales, incluyendo trastornos relacionados con la tension.
WO2005079756A2 (en) * 2004-02-13 2005-09-01 Neuromolecular, Inc. Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
EP1858515A2 (en) * 2005-03-04 2007-11-28 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
CN101257907A (zh) * 2005-07-06 2008-09-03 塞普拉科公司 左旋佐匹克隆和抗抑郁剂的组合
US20100105748A1 (en) * 2007-03-16 2010-04-29 David Weinshenker Methods and compositions for treatment of drug addiction
WO2009015244A1 (en) * 2007-07-23 2009-01-29 Synosia Therapeutics Rufinamide for the treatment of post-traumatic stress disorder

Also Published As

Publication number Publication date
JP2010534676A (ja) 2010-11-11
CA2707858A1 (en) 2009-01-29
WO2009015248A1 (en) 2009-01-29
AU2008279091A1 (en) 2009-01-29
US20090054403A1 (en) 2009-02-26
RU2010106014A (ru) 2011-08-27
EP2182952A1 (en) 2010-05-12
RU2458691C2 (ru) 2012-08-20
EP2182952A4 (en) 2010-09-08
CN101951912A (zh) 2011-01-19
SG183069A1 (en) 2012-08-30
NZ583193A (en) 2012-05-25
CO6260078A2 (es) 2011-03-22

Similar Documents

Publication Publication Date Title
CO6260078A2 (es) Metodo y tratamiento del trastorno por estres postraumatico mediante la administracion de un agente seleccionado entre benzodiazepina, un inhibidor (isrs) y otros
MX2009012307A (es) Tratamiento de sinucleinopatias.
MX2010006823A (es) Metodos para el tratamiento de la gota.
EA201001771A1 (ru) Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью
WO2013033657A3 (en) CaMKII, IP3R, CALCINEURIN, P38 AND MK2/3 INHIBITORS TO TREAT METABOLIC DISTURBANCES OF OBESITY
PH12013500808A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
NO20082473L (no) Fremgangsmater, sammensetninger og sett for behandling av medisinske tilstander
MX391921B (es) Nepicastat para usarse en el tratamiento de dependencia
MX2010001993A (es) Metodos y composiciones para diagnosticar una enfermedad.
TN2011000413A1 (en) Sglt-2inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus impaired glucose tolerance or hyperglycemia
WO2007103373A3 (en) Compositions and methods for the treatment of immunoinflammatory disorders
AR065033A1 (es) Metodos para prevenir y tratar trastornos neurodegenerativos
NZ603717A (en) Suture line administration technique using botulinum toxins
WO2010151755A3 (en) TREATMENT OF INFLAMMATORY DISEASES USING miR-124
MX2009013649A (es) Variantes geneticas en el cromosoma 15q24 como marcadores para usarse en diagnostico, prognosis y tratamiento de sindrome de exfoliacion y glaucoma.
UA113849C2 (xx) Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу
MX2009008135A (es) Uso de histidinato de cromo para tratamiento de alteraciones cardiometabolicas.
MX2011008994A (es) Metodos de usar sns - 595 para el tratamiento de sujetos con cancer con actividad reducida de brca2.
MX2011012666A (es) Usos de anticuerpos il-1beta y sus fragmentos de union relacionados con eventos cardiovasculares.
MX2010000938A (es) Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del ácido 4-hidroxi-4-metil-piperidin-1-carboxílico para el tratamiento del trastorno por estrés postraumático.
NZ611614A (en) Compositions and methods for treating amyloid plaque associated symptoms
WO2006012641A3 (en) Methods for detecting and treating autoimmune disorders
WO2006113900A3 (en) Methods and devices for relieving stress
IN2012DN00549A (cg-RX-API-DMAC7.html)
EP2566502A4 (en) METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: BIOTIE THERAPIES, INC.*

FA Abandonment or withdrawal